Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

UPDATE: Perspective Therapeutics Q2 EPS $(0.17) Beats $(0.21) Estimate, Sales $526.00K Beat $60.00K Estimate

Author: Benzinga Newsdesk | August 12, 2024 04:23pm

Perspective Therapeutics (AMEX:CATX) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.21) by 19.05 percent. This is a 50 percent increase over losses of $(0.34) per share from the same period last year. The company reported quarterly sales of $526.00 thousand which beat the analyst consensus estimate of $60.00 thousand by 776.67 percent. This is a 10.54 percent decrease over sales of $588.00 thousand the same period last year.

Posted In: CATX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist